Literature DB >> 12003247

The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer disease.

R A Sweet1, B G Pollock, D L Sukonick, B H Mulsant, J Rosen, W E Klunk, K B Kastango, S T DeKosky, R E Ferrell.   

Abstract

BACKGROUND: Psychotic symptoms in subjects with Alzheimer disease (AD+psychosis, AD+P) are a marker for a distinct phenotype characterized by more rapid cognitive and functional decline and a liability to aggressive behaviors. We recently found that AD subjects homozygous for long alleles (l) of an insertion/deletion polymorphism in the promoter region of the serotonin transporter (5-HTTPR) had elevated rates of aggressive behavior.
OBJECTIVE: To examine whether the 5-HTTPR ll genotype confers an increased risk of AD+P, and of the combined AD+P/aggressive phenotype.
METHODS: The 5-HTTPR genotype was determined in 332 subjects diagnosed with possible or probable AD. All subjects received structured psychiatric assessments and were categorized with regard to their history of aggressive behaviors and psychotic symptoms.
RESULTS: Consistent with other reports, AD+P was associated with a significant increased risk for aggressive behavior. AD+P and aggression were both significantly associated with 5-HTTPR ll genotype and with an increased l allele frequency. Subjects with the combined behavioral phenotype (AD+P and aggressive behavior) had the highest rate of ll genotype and highest l allele frequency.
CONCLUSION: The 5-HTTPR l allele appears to confer risk for the combined AD+P/aggressive phenotype. Confirmation of this association in a similar behaviorally well-characterized independent sample is needed.

Entities:  

Mesh:

Year:  2001        PMID: 12003247     DOI: 10.1017/s1041610201007827

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  28 in total

Review 1.  Genetics of psychosis of Alzheimer disease.

Authors:  Chintan Shah; Mary Ann A DeMichele-Sweet; Robert A Sweet
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2016-01-12       Impact factor: 3.568

2.  Incident Psychosis in Subjects With Mild Cognitive Impairment or Alzheimer's Disease.

Authors:  Elise A Weamer; Mary Ann A DeMichele-Sweet; Yona K Cloonan; Oscar L Lopez; Robert A Sweet
Journal:  J Clin Psychiatry       Date:  2016-12       Impact factor: 4.384

3.  Association study of polymorphisms in LRP1, tau and 5-HTT genes and Alzheimer's disease in a sample of Colombian patients.

Authors:  D A Forero; G Arboleda; J J Yunis; R Pardo; H Arboleda
Journal:  J Neural Transm (Vienna)       Date:  2005-12-14       Impact factor: 3.575

4.  Effects of Vitamin D Use on Outcomes of Psychotic Symptoms in Alzheimer Disease Patients.

Authors:  Lirong Wang; Jian Ying; Peihao Fan; Elise A Weamer; Mary Ann A DeMichele-Sweet; Oscar L Lopez; Julia K Kofler; Robert A Sweet
Journal:  Am J Geriatr Psychiatry       Date:  2019-03-27       Impact factor: 4.105

5.  Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms.

Authors:  Alexandre Y Dombrovski; Benoit H Mulsant; Robert E Ferrell; Francis E Lotrich; Jules I Rosen; Meredith Wallace; Patricia R Houck; Sati Mazumdar; Bruce G Pollock
Journal:  Int Clin Psychopharmacol       Date:  2010-01       Impact factor: 1.659

Review 6.  Antiepileptic drugs for the treatment of agitation and aggression in dementia: do they have a place in therapy?

Authors:  Damien Gallagher; Nathan Herrmann
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

7.  TAR DNA-binding protein 43 pathology in Alzheimer's disease with psychosis.

Authors:  Anil Varma V Vatsavayi; Julia Kofler; Mary Ann A Demichele-Sweet; Patrick S Murray; Oscar L Lopez; Robert A Sweet
Journal:  Int Psychogeriatr       Date:  2014-03-04       Impact factor: 3.878

8.  Risk Factors, Neuroanatomical Correlates, and Outcome of Neuropsychiatric Symptoms in Alzheimer's Disease.

Authors:  Stéphane P Poulin; David Bergeron; Bradford C Dickerson
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

9.  Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease.

Authors:  Paula T Trzepacz; Jeffrey Cummings; Thomas Konechnik; Tammy D Forrester; Curtis Chang; Ellen B Dennehy; Brian A Willis; Catherine Shuler; Linda B Tabas; Constantine Lyketsos
Journal:  Int Psychogeriatr       Date:  2012-12-21       Impact factor: 3.878

Review 10.  The role of the serotonergic system at the interface of aggression and suicide.

Authors:  M Bortolato; N Pivac; D Muck Seler; M Nikolac Perkovic; M Pessia; G Di Giovanni
Journal:  Neuroscience       Date:  2013-01-16       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.